I MÃ¡rquez-Rodas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3581490/publications.pdf

Version: 2024-02-01

128 papers	20,524 citations	147801 31 h-index	31849 101 g-index
131 all docs	131 docs citations	131 times ranked	22876 citing authors

#	Article	IF	Citations
1	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	1.6	446
2	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR Cancer, 2022, 8, e35930.	2.4	7
3	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600â€“mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.. Journal of Clinical Oncology, 2022, 40, 9540-9540.	1.6	5
4	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. Journal of Clinical Oncology, 2022, 40, 9522-9522.	1.6	37
5	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. Scientific Reports, 2021, 11, 7064.	3.3	13
6	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
7	SEOM clinical guideline for the management of cutaneous melanoma (2020). Clinical and Translational Oncology, 2021, 23, 948-960.	2.4	22
8	COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study. Journal of the American Academy of Dermatology, 2021, 84, 1412-1415.	1.2	5
9	Â¿Cuando merece la pena realizar una linfadenectomÃa en pacientes con micrometÃ¡stasis de melanoma en ganglio centinela? Un anÃ¡lisis retrospectivo de 20 aÃ±os de experiencia. CirugÃa Y Cirujanos, 2021, 89, 457-460.	0.1	0
10	Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy. Cancer Research, 2021, 81, CT233-CT233.	0.9	1
11	CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma. Cancers, 2021, 13, 3943.	3.7	8
12	Venous thromboembolism incidence in cancer patients with germline BRCA mutations. Clinical and Translational Oncology, 2021, , 1.	2.4	1
13	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
14	1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study. Annals of Oncology, 2021, 32, S881-S882.	1.2	1
15	1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial. Annals of Oncology, 2021, 32, S870.	1.2	3
16	Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. Clinical and Translational Oncology, 2020, 22, 717-724.	2.4	7
17	Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. Clinical and Translational Oncology, 2020, 22, 555-562.	2.4	14
18	Utility of PET/CT in patients with stage Iâ€“III melanoma. Clinical and Translational Oncology, 2020, 22, 1414-1417.	2.4	6

#	Article	IF	Citations
19	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs, 2020, 80, 131-146.	10.9	10
20	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	1.2	132
21	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic antiâ€“PD-1 for patients with antiâ€“PD-1â€“refractory tumors. Science Translational Medicine, 2020, 12, .	12.4	51
22	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. Annals of Oncology, 2020, 31, S734-S735.	1.2	8
23	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1449-1461.	1.2	69
24	Adjuvant nivolumab versus ipilimumab in resected stage IIIBâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	10.7	330
25	1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. Annals of Oncology, 2020, 31, S731-S732.	1.2	7
26	LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Annals of Oncology, 2020, 31, S1173.	1.2	21
27	LBA66_PR Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Annals of Oncology, 2020, 31, S1196.	1.2	4
28	Prognostic significance of sentinel node biopsy status in cutaneous melanoma: a 21-years prospective study from a single institution. Clinical and Translational Oncology, 2020, 22, 1611-1618.	2.4	0
29	Patterns of disease presentation, treatment choices and survival in real world for patients diagnosed with advanced melanoma: A prospective observational study by Spanish Melanoma Group (GEM-1801).. Journal of Clinical Oncology, 2020, 38, e22022-e22022.	1.6	0
30	A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain. Clinical and Translational Oncology, 2019, 21, 1754-1762.	2.4	1
31	Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Annals of Oncology, 2019, 30, v533-v534.	1.2	65
32	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	2.8	27
33	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	2.8	61
34	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	27.0	2,484
35	The RANKâ€“RANKL axis: an opportunity for drug repurposing in cancer?. Clinical and Translational Oncology, 2019, 21, 977-991.	2.4	31
36	Melanoma proteomics suggests functional differences related to mutational status. Scientific Reports, 2019, 9, 7217.	3.3	10

#	Article	IF	Citations
37	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
38	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	27.8	313
39	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. Journal of Clinical Oncology, 2019, 37, 867-875.	1.6	258
40	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. Oncologist, 2019, 24, 1375-1383.	3.7	22
41	Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer. Annals of Oncology, 2019, 30, xi37-xi38.	1.2	2
42	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. JCO Precision Oncology, 2019, 3, 1-16.	3.0	7
43	For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity. Clinical Cancer Research, 2019, 25, 1127-1129.	7.0	4
44	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. Journal of Clinical Oncology, 2019, 37, 9584-9584.	1.6	6
45	P162â€...Lynch syndrome followed up in a hereditary gynaecological cancer unit. , 2019, , .		0
46	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clinical Cancer Research, 2018, 24, 1845-1852.	7.0	84
47	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774974.	3.2	200
48	CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma. Cancer Immunology Research, 2018, 6, 267-275.	3.4	49
49	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling, 2018, 27, 854-862.	1.6	5
50	SEOM clinical guideline for the management of malignant melanoma (2017). Clinical and Translational Oncology, 2018, 20, 69-74.	2.4	16
51	Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). Annals of Oncology, 2018, 29, viii735.	1.2	3
52	Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Annals of Oncology, 2018, 29, viii737.	1.2	8
53	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. Annals of Oncology, 2018, 29, viii732.	1.2	8
54	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1480-1492.	10.7	1,089

#	ARTICLE	IF	CITATIONS
55	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. Melanoma Research, 2018, 28, 333-340.	1.2	13
56	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clinical Cancer Research, 2018, 24, 5820-5829.	7.0	82
57	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	7.0	108
58	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	1.6	458
59	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. Clinical and Translational Oncology, 2017, 19, 761-768.	2.4	12
60	Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis. Clinical and Translational Oncology, 2017, 19, 1055-1057.	2.4	2
61	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 863-873.	10.7	561
62	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Research and Treatment, 2017, 162, 181-189.	2.5	11
63	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	27.0	1,752
64	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	27.0	3,589
65	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Future Oncology, 2017, 13, 2137-2149.	2.4	7
66	Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital. Oncology, 2017, 92, 68-74.	1.9	2
67	Burden of Healthcare Costs for Merkel Cell Carcinoma Management in Spain. Value in Health, 2017, 20, A427.	0.3	0
68	Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy, 2017, 17, 669-679.	2.4	22
69	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. JAMA Oncology, 2017, 3, 1511.	7.1	131
70	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. Medicine (United States), 2017, 96, e9523.	1.0	6
71	Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. Annals of Oncology, 2017, 28, v135.	1.2	0
72	Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial. Annals of Oncology, 2017, 28, v612.	1.2	2

#	Article	IF	Citations
73	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 390-390.	1.7	0
74	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM â€œEl Ã‰lamo IIIâ€• retrospective study. PLoS ONE, 2017, 12, e0184181.	2.5	0
75	Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population. Annals of Oncology, 2017, 28, v56.	1.2	0
76	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). Annals of Oncology, 2017, 28, v632-v633.	1.2	6
77	Predictive factors of response to immunotherapyâ€”a review from the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 389-389.	1.7	26
78	Abstract P4-20-01: Implications of financial modeling in breast cancer clinical research from 1990 to 2010. , 2017, , .		0
79	Highlights of the season 2016â€“2017 by the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 391-391.	1.7	0
80	Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3. Tumori, 2016, 102, S54-S56.	1.1	4
81	The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. Journal of Gynecologic Oncology, 2016, 27, e7.	2.2	30
82	Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation. Annals of Oncology, 2016, 27, vi465.	1.2	0
83	Treatment patterns of adjuvant interferon-Î±2b for high-risk melanoma: a retrospective study of the Grupo EspaÃ±ol Multidisciplinar de Melanoma â€“ Prima study. Melanoma Research, 2016, 26, 278-283.	1.2	8
84	Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC). Annals of Oncology, 2016, 27, vi56.	1.2	0
85	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Research and Treatment, 2016, 156, 507-515.	2.5	27
86	Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. Journal of the American Academy of Dermatology, 2016, 75, 967-974.	1.2	61
87	GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases. Annals of Oncology, 2016, 27, vi383.	1.2	0
88	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
89	Review: circulating tumor cells in the practice of breast cancer oncology. Clinical and Translational Oncology, 2016, 18, 749-759.	2.4	7
90	Abstract P1-10-10: An integrative intervention to change breast cancer patients' lifestyle: A medical challenge. A randomize controlled trial. , 2016, , .		0

#	Article	IF	Citations
91	MicroRNA expression signatures for the prediction of BRCA1/2 mutationâ€associated hereditary breast cancer in paraffinâ€embedded formalinâ€fixed breast tumors. International Journal of Cancer, 2015, 136, 593-602.	5.1	43
92	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	27.0	6,773
93	Deletion at 6q24.2â€“26 predicts longer survival of highâ€grade serous epithelial ovarian cancer patients. Molecular Oncology, 2015, 9, 422-436.	4.6	17
94	Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. Breast Cancer Research and Treatment, 2015, 153, 371-382.	2.5	73
95	Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. Clinical and Translational Oncology, 2015, 17, 180-196.	2.4	47
96	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	2.5	8
97	Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267.	1.7	47
98	Abstract P5-15-08: Exercise intervention to run away from breast cancer treatment side effects: An integrative approach. , 2015, , .		0
99	A Multidisciplinary Approach to Heredofamilial Cancer Syndromes: Evaluation of the First Four Years of Experience at a Spanish University Hospital. Annals of Oncology, 2014, 25, iv166.	1.2	0
100	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. Journal of Genetic Counseling, 2014, 23, 108-113.	1.6	3
101	Cost-Effectiveness of Ipilimumab for Previously Untreated Patients with Advanced Metastatic Melanoma in Spain. Value in Health, 2014, 17, A631.	0.3	3
102	Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside. Current Breast Cancer Reports, 2014, 6, 79-87.	1.0	3
103	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori, 2014, 100, 144e-7e.	1.1	2
104	MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. British Journal of Cancer, 2013, 109, 2724-2734.	6.4	23
105	Cambios epidemiolÃ³gicos en el melanoma cutÃ¡neo: estudio retrospectivo de 969 casos (1996-2010). Revista Clinica Espanola, 2013, 213, 81-87.	0.6	10
106	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. Oncologist, 2013, 18, 917-923.	3.7	41
107	619 Deciphering Non-BRCA1/2 Familial Breast Tumor Heterogeneity by MiRNA Expression Profiling. European Journal of Cancer, 2012, 48, S147.	2.8	0
108	Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study. Oncology, 2012, 82, 30-34.	1.9	7

#	Article	IF	Citations
109	Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene. PLoS ONE, 2012, 7, e38847.	2.5	71
110	The Implementation of a Multidisciplinary Heredofamilial Cancer Unit Changes Hereditary Cancer Risk Perception among Oncologists. Annals of Oncology, 2012, 23, ix176-ix177.	1.2	0
111	Neratinib (HKI-272) in the treatment of breast cancer. Future Oncology, 2012, 8, 671-681.	2.4	26
112	Abstract 5051: microRNA based classification of non-BRCA1/2 hereditary breast cancer tumors. , 2012, , .		0
113	Family history record and hereditary cancer risk perception after the creation of a heredofamilial cancer unit in a Spanish hospital.. Journal of Clinical Oncology, 2012, 30, e12003-e12003.	1.6	0
114	3540 POSTER Perception of Hereditary Cancer Risk in a Medical Oncology Service: a Retrospective Study. European Journal of Cancer, 2011, 47, S258.	2.8	1
115	Cirrhosis decreases vasoconstrictor response to electrical field stimulation in rat mesenteric artery: role of calcitonin gene-related peptide. Experimental Physiology, 2011, 96, 275-286.	2.0	15
116	A new era in the treatment of melanoma: from biology to clinical practice. Clinical and Translational Oncology, 2011, 13, 787-792.	2.4	9
117	Melanoma de uretra masculina: caso clÃnico. Actas UrolÃ³gicas EspaÃ±olas, 2010, 34, 651-652.	0.7	1
118	Melanoma of male urethra: A clinical case. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2010, 34, 651-652.	0.2	0
119	Utilidad de la tomografÃa por emisiÃ³n de positrones en el diagnÃ³stico del nÃ³dulo pulmonar solitario con alta probabilidad de malignidad. Revista De Patologia Respiratoria, 2009, 12, 69-73.	0.0	0
120	Primary ovarian Burkitt lymphoma. Clinical and Translational Oncology, 2008, 10, 673-675.	2.4	9
121	Increased expression in calcitonin-like receptor induced by aldosterone in cerebral arteries from spontaneously hypertensive rats does not correlate with functional role of CGRP receptor. Regulatory Peptides, 2008, 146, 125-130.	1.9	7
122	Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway. Cardiovascular Research, 2007, 75, 398-407.	3.8	20
123	Aldosterone increases RAMP1 expression in mesenteric arteries from spontaneously hypertensive rats. Regulatory Peptides, 2006, 134, 61-66.	1.9	18
124	Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension. Journal of Physiology and Biochemistry, 2006, 62, 45-56.	3.0	38
125	Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats. Hypertension, 2005, 46, 107-112.	2.7	115
126	Protein kinase A increases electrical stimulation-induced neuronal nitric oxide release in rat mesenteric artery. European Journal of Pharmacology, 2004, 487, 167-173.	3.5	18

#	ARTICLE	IF	CITATIONS
127	Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide. Regulatory Peptides, 2004, 120, 253-260.	1.9	28
128	Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats. Journal of Hypertension, 2004, 22, 949-957.	0.5	25